Models, Mechanisms, and Biomarkers of Prostate Cancer Progression

Dear Colleague, 

Metastatic prostate cancer (PCa) represents a clinical challenge and a leading cause of mortality in men around the world. While targeting the androgen receptor is the standard of care, mechanisms of resistance inevitably occur, requiring the development of novel therapeutic strategies.

A better understanding of the biological mechanisms driving PCa progression and the identification of informative biomarkers for patient stratification are thus crucial to improve the treatment of metastatic PCa.

This Special Issue covers emerging mechanistic aspects and architectural features involved in PCa progression, including metabolic reprogramming, tumor microenvironment remodeling, epigenetic rewiring, and intraductal pathology.

The pitfalls of currently in-use therapies and the limits of available preclinical models are also discussed in the perspective to improve the management of metastatic PCas.

Finally, this Issue addresses the clinical impact of the genomic and metabolomic heterogeneity of metastatic PCa and the current challenges in identifying accurate predictive and prognostic biomarkers for the design of personalized treatments.

Any experimental and clinical work relevant to this Special Issue is very welcome.

Dr. Giorgia Zadra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.